Serono SA signed a licensing agreement with OSI Pharmaceuticals Inc., granting OSI exclusive rights to market and promote Novantrone in the U.S. in its approved oncology indications. (BioWorld International)

Serono SA signed a licensing agreement with OSI Pharmaceuticals Inc., granting OSI exclusive rights to market and promote Novantrone in the U.S. in its approved oncology indications. (BioWorld International)